StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis 2. Immunology by Quarter

2. Immunology ($M)

QuarterlyAnnual

Novartis 2. Immunology: $2,880M in Q3 2026, up 10.3% from a year earlier. That is the highest of the 16 quarters on record here.

Latest, Q3 2026
2,880
Period ended Sep 30, 2026
Change on a year earlier
+10.3%
2,611 in Q3 2025
History
16 quarters
Since Q4 2022
Sources
12
Documents cited below

Where the Q3 2026 figure comes from

“|| Total immunology | 2 880 | 2 611 | 10 | 10”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K (Net sales by therapeutic area) & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEnded2. Immunology ($M)Year on yearSource
Q3 2026Sep 30, 20262,880+10.3%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20262,780+9.1%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 20262,466+2.4%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 20252,724+13.1%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20252,611+5.2%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 20252,549+9.8%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 20252,409+15.8%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 20242,408+17.1%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 20242,483+22.1%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 20242,321+19.0%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 20242,081+18.4%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 20232,057+20.7%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 20232,033–Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 20231,950–Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 20231,758–Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 20221,704–Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up 2. Immunology

Cite this data

StockData. (2026). Novartis 2. Immunology ($M), quarterly Q4 2022–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-immunology

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.